Want to join the conversation?
$REGN will be starting a 10,000 patient long-term treatment phase 3 clinical study of Fasinumab in 1H16. The company anticipates reporting data from a 16-week study in osteoarthritis pain in 1H16. In the early-stage pipeline, $REGN will share data from phase 1 and 2 studies of Evinacumab, antibody ANGPTL3 for dyslipidemia in 1H16.
$DB is going to cut off services for about 3,400 clients in equities trading.
$F stock slid more than 2% after the company issued two safety recalls involving more than 650,000 Ford Fusion and Lincoln MKZ model cars.
The new CEO of $SBUX, Kevin Johnson, has some pretty large shoes to fill but there are many who have good faith in his ability to do so.
$TSLA opening a showroom in Michigan. A bold move !!